Matt joined the Board of Trustees of Prostate Cancer Research in 2016 and has been Chair of Trustees since 2018.

Matt is also a Director of Cambridge spin-out Constructive Bio, whose platform technologies allow the fundamental reprogramming of the genetic code to create new classes of enzymes, pharmaceuticals and biomaterials.

Prior to this, Matt worked in investment banking for 15 years, advising on over $300bn of M&A transactions and over $3bn of equity fundraising for some of the largest companies in the UK.